
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech has demonstrated significant growth in its surgical and soft tissue repair product segments, with sales increasing 24% year-over-year to $23.4 million, primarily driven by the demand for CellerateRX Surgical Activated Collagen. Additionally, the company’s strategic focus on expanding its distribution network and increasing penetration in healthcare facilities is expected to further enhance topline growth. With revenue projections for the upcoming 12 months showing positive trends, continuing operations are anticipated to become profitable by the third quarter of 2025.
Bears say
Sanara MedTech Inc. reported net revenue of $26.3 million, indicating a year-over-year growth of 21.5%, which fell slightly short of expectations of $26.7 million. The company faces several substantial risks that contribute to a negative financial outlook, including lower-than-expected revenue growth, challenges in acquiring new customers, delays in product launches, and potential dilution of shareholder value. Additionally, the company has decreased its enterprise value to revenue multiple from 4.3x to 3.0x, reflecting the removal of telehealth from its business strategy and suggesting concerns regarding its future revenue-generating potential.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares